Interesting how people interpret the same thing differently.
If (i) SOZO is truly the only device to capitalize on NCCN guidslines and (ii) the opportunity is as big as the CEO is presenting (he said this--single-company licence to captuere the market and surge in demand--has never/rarely happened in medical devices: it happens in drugs, but not medical devices; I listened the quarterly multiple times!): then the concern should be on take-overs given the tiny market cap compared to the (low-hanging fruit) opportunity.
Add to My Watchlist
What is My Watchlist?
